The trial is taking place at:
P

Peak Gastroenterology Associates | Peak Gastro Colorado Springs

Veeva-enabled site

An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis (ELEVATE UC OLE)

Pfizer logo

Pfizer

Status and phase

Enrolling
Phase 3

Conditions

Ulcerative Colitis

Treatments

Drug: Etrasimod

Study type

Interventional

Funder types

Industry

Identifiers

NCT03950232
APD334-303
C5041012 (Other Identifier)

Details and patient eligibility

About

The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely active ulcerative colitis (UC) who previously received double-blind treatment (either etrasimod 2 mg per day or placebo) during participation in one of the qualified Phase 3 or Phase 2 double-blind, placebo-controlled parent studies including but not limited to: (APD334-301 \[NCT03945188\] or APD334-302 \[NCT03996369\] or APD334-210 \[NCT04607837\]).

Enrollment

912 estimated patients

Sex

All

Ages

16 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

* Must have met the eligibility criteria and have been enrolled in the qualified Phase 2 or 3 parent studies listed below or other qualified region-specific studies and meet the following additional criteria: 1. Participants previously enrolled in Study APD334-301 (NCT03945188) or APD334-210 (NCT04607837) must have completed the Week 12 visit and have been assessed to have active UC that has not improved or has worsened from baseline or completed the Week 52 visit 2. Participants previously enrolled in APD334-302 (NCT03996369) must have completed the Week 12 visit

Exclusion criteria

* If Investigator considers the participant to be unsuitable for any reason to participate in the Open-Label Extension study * Experienced an adverse event that led to discontinuation from parent study

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

912 participants in 1 patient group

Etrasimod 2 mg
Experimental group
Treatment:
Drug: Etrasimod

Trial contacts and locations

619

Loading...

Central trial contact

Pfizer CT.gov Call Center

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems